Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial - PubMed
2 hours ago
- #Clinical Trial
- #Neoantigen Vaccine
- #Glioblastoma
- Phase 1 trial tested GNOS-PV01, a personalized DNA vaccine for MGMT unmethylated glioblastoma.
- Primary endpoints were safety and feasibility; no serious adverse events occurred in nine vaccinated patients.
- Vaccine induced peripheral T-cell activation in most patients, except one on dexamethasone.
- Secondary endpoints included 66.7% 6-month progression-free survival and 12-month overall survival.
- Median progression-free survival was 8.5 months, median overall survival 16.3 months, with 33% survival at 24 months.
- Trial supports GNOS-PV01 as a potential impactful component in glioblastoma immunotherapy.